The Prevalence of Secondary Adrenal Insufficiency in Patients With Exacerbation of COPD in Glucocorticoid Treatment Related to Differenct Gene Polymorphisms of the Glucocorticoid Receptor Gene

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

78 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-08-17

Study Completion Date

2020-05-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate the correlation between four well-known polymorphisms of the glucocorticoid receptor gene (two with reduced sensitivity versus two with increased sensitivity) and the prevalence of secondary adrenal insufficiency in glucocorticoid-treated patients with exacerbation of COPD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Relationship Between Plasma Metabolome and the Efficacy of Systemic Glucocorticoid in AECOPD

NCT04710849

COPD COPD Exacerbation Acute

UNKNOWN

Predictors of Acute Exacerbation in Patients With COPD - an Observational Study

NCT04140097

Chronic Obstructive Pulmonary Disease COPD COPD Exacerbation +1 more

ACTIVE_NOT_RECRUITING

Analysis of Relationship Between Metabolic Biomarkers and Efficacy of Glucocorticoid in AECOPD

NCT04964037

Chronic Obstructive Pulmonary Disease

COMPLETED

Nutritional Status in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

NCT03709498

Pulmonary Disease, Chronic Obstructive

COMPLETED

Diastolic Dysfunction and Pauci-inflammatory Acute Exacerbations of COPD

NCT03110614

Chronic Obstructive Pulmonary Disease Diastolic Dysfunction

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

COPD patients who have received systemic glucocorticoid exceeding the equivalent of 180 mg prednisolone which are homo / heterozygous for the BclI and / or N363S polymorphisms (associated with increased glucocorticoid sensitivity) will have a lower cortisol response in a synacthen® test (greater suppression of adrenal corticosteroid) than the corresponding patients there are wild-type or homo- or heterozygous for the polymorphic ER22 / 23EK and / or 9β (associated with decreased sensitivity). Information from the results of the investigation will be able to help clinicians to identify patients with acute exacerbation of COPD (AECOPD) at risk of of secondary adrenal insufficiency.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adrenal Insufficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients \> 18 years
* Caucasian classified with COPD
* Patients with AECOPD being treated with at least 5 days of glucocorticoid (minimum of 180 mg)

Exclusion Criteria

* Treated with estrogen-containing medications, including anticonceptiva 6 weeks prior to Synacthen®
* Pregnancy or lactation
* on regular systemic glucocorticoid therapy before admission to the hospital
* People who are detained under the act on the use of coercion in psychiatry
* Severe language problems or inability to provide written informed consent

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No